Evidence map›Paper›PMID 34727272›Full record

Trial reportAIDS and behavior2022

Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.

Juliane Etima, Ariana W K Katz, Zoe Duby, Morgan Garcia, Thesla Palanee-Phillips, Krishnaveni Reddy, Florence Mathebula, Chifundo Zimba, Leila E Mansoor, Devika Singh and 5 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Juliane EtimaMakerere University-Johns Hopkins University Research Collaboration, Upper Mulago Hill Road, P. O. Box 23491, Kampala, Uganda. jetima@mujhu.org.ORCID http://orcid.org/0000-0002-5879-6000
Ariana W K KatzWomen's Global Health Imperative, RTI International, Berkeley, CA, USA.
Zoe DubyDivision of Social and Behavioural Sciences in the School of Public Health and Family Medicine, University of Cape Town, Rondebosch, Cape Town, South Africa.
Morgan GarciaFHI360, Durham, USA.
Thesla Palanee-PhillipsWits Reproductive Health and HIV Institute, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Krishnaveni ReddyWits Reproductive Health and HIV Institute, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Florence MathebulaWits Reproductive Health and HIV Institute, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Chifundo ZimbaUNC-Lilongwe, Lilongwe, Malawi.
Leila E MansoorCentre for the AIDS Programme of Research in South African (CAPRISA), Durban, South Africa.
Devika SinghMagee-Womens Research Institute, Pittsburgh, PA, USA.
Elmah ManengamamboUniversity of Zimbabwe College of Health Sciences Clinical Trials Research Centre (UZCHS-CTRC), Harare, Zimbabwe.
Sarita NaidooHIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.
Lydia Soto-TorresDivision of AIDS, NIH, Bethesda, MD, USA.
Elizabeth T MontgomeryWomen's Global Health Imperative, RTI International, Berkeley, CA, USA.
MTN-020/ASPIRE, MTN 025/HOPE, MTN-032 Study teams

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
Eunice Kennedy Shriver National Institute of Child Health and Human Development UM1AI068615Eunice Kennedy Shriver National Institute of Child Health and Human Development UM1AI068633Eunice Kennedy Shriver National Institute of Child Health and Human Development UM1AI106707National Institute of Allergy and Infectious Diseases UM1AI068615National Institute of Allergy and Infectious Diseases UM1AI068633National Institute of Allergy and Infectious Diseases UM1AI106707NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI068633NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

As demonstrated by the Phase III clinical trial, MTN-020/ASPIRE, the monthly dapivirine vaginal ring is well tolerated and reduces the risk of HIV-1 as a woman-initiated prevention option. This analysis uses data from the follow-on MTN-032/Assessment of ASPIRE and HOPE Adherence (AHA) qualitative study to understand how perceptions (or misperceptions) of ring efficacy may have influenced behavior during ASPIRE, and affected intention to use the ring in future ring projects, specifically HOPE, the planned open-label extension study. Single in-depth interviews (n = 98) and 12 focus group discussions (n = 89) were conducted with women at seven sites in Malawi, South Africa, Uganda and Zimbabwe. Eligibility included participation in the ASPIRE active arm, and ring use for ≥ 3 months or at least 1 month if seroconversion occurred. Interviews were audio-recorded, transcribed into English, coded in Dedoose and thematically analyzed. Demographic and behavioral questionnaire data were summarized in Stata. Most AHA participants perceived the ring to be effective, and described simply trusting it or having confidence in it because they, or other participants in risky situations, remained HIV-uninfected. Participants described ring efficacy after receiving ASPIRE results as a binary assessment: the ring worked or not. Many did not remember exact efficacy percentages because of lack of comprehension or memory but recalled key details about age differences. The majority expressed interest in future ring use. There is a need to investigate improved ways of explaining placebo-controlled trials and efficacy to women in Sub-Saharan Africa. Now that ring efficacy, is known, these benefits must be well communicated, and understood by end-users and key stakeholders. Engagement with end-users to construct effective messages and to develop tools to measure understanding of partial efficacy will be essential.

Indexed as

Anti-HIV AgentsContraceptive Devices, FemaleHIV InfectionsFemaleHumansPyrimidinesAnti-HIV AgentsDapivirinePyrimidinesDapivirine vaginal ringEfficacyPerceptionsUnderstanding

Identifiers

PMID34727272
PMCPMC9007827

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.